The Role of Lipoprotein-Associated Phospholipase A2 as a Marker and Potential Therapeutic Target in Atherosclerosis

被引:22
作者
Stewart, Ralph A. H. [1 ]
White, Harvey D. [1 ]
机构
[1] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland 1030, New Zealand
关键词
darapladib; Lp-PLA(2); plaque stabilization; atherosclerosis; cardiovascular disease; ACTIVATING-FACTOR-ACETYLHYDROLASE; CORONARY-HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; PLASMA; RISK; EXPRESSION; DARAPLADIB; PLAQUE; LYSOPHOSPHATIDYLCHOLINE; INHIBITOR;
D O I
10.1007/s11883-010-0158-8
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an enzyme that generates inflammatory mediators within atherosclerotic plaques. In epidemiologic studies there is an association between higher plasma Lp-PLA(2) activity and myocardial infarction, stroke and cardiovascular mortality. In animal models, darapladib, a specific inhibitor of Lp-PLA(2,) decreases the size of the atheroma necrotic core and plaques with thin fibrous caps. Early clinical trials suggest darapladib effectively and safely inhibits Lp-PLA(2) activity both in plasma and in carotid atheroma. Two large phase III clinical trials that are currently in progress will determine whether darapladib will reduce the risk of myocardial infarction, stroke, and cardiovascular death by stabilizing atherosclerotic plaques.
引用
收藏
页码:132 / 137
页数:6
相关论文
共 23 条
[1]   Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma [J].
Asano, K ;
Okamoto, S ;
Fukunaga, K ;
Shiomi, T ;
Mori, T ;
Iwata, M ;
Ikeda, Y ;
Yamaguchi, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 261 (02) :511-514
[2]   PLA2G7 Genotype, Lipoprotein-Associated Phospholipase A2 Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European Ancestry [J].
Casas, Juan P. ;
Ninio, Ewa ;
Panayiotou, Andrie ;
Palmen, Jutta ;
Cooper, Jackie A. ;
Ricketts, Sally L. ;
Sofat, Reecha ;
Nicolaides, Andrew N. ;
Corsetti, James P. ;
Fowkes, F. Gerry R. ;
Tzoulaki, Ioanna ;
Kumari, Meena ;
Brunner, Eric J. ;
Kivimaki, Mika ;
Marmot, Michael G. ;
Hoffmann, Michael M. ;
Winkler, Karl ;
Maerz, Winfred ;
Ye, Shu ;
Stirnadel, Heide A. ;
Khaw, Kay-Tee ;
Humphries, Steve E. ;
Sandhu, Manjinder S. ;
Hingorani, Aroon D. ;
Talmud, Philippa J. .
CIRCULATION, 2010, 121 (21) :2284-U74
[3]  
*GLAXOSMITHKLINE, STAB PLAQ DAR THROMB
[4]  
*HEART PROT STUD C, 2010, J INTERN MED, DOI DOI 10.1111/J.1365-2796.2010.02258.X
[5]   Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcome [J].
Herrmann, Joerg ;
Mannheim, Dallit ;
Wohlert, Christine ;
Versari, Daniele ;
Meyer, Fredric B. ;
McConnell, Joseph P. ;
Goessl, Mario ;
Lerman, Lilach O. ;
Lerman, Amir .
EUROPEAN HEART JOURNAL, 2009, 30 (23) :2930-2938
[6]   Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study [J].
Hou, Liping ;
Chen, Shufeng ;
Yu, Hongjiang ;
Lu, Xiangfeng ;
Chen, Jianhong ;
Wang, Laiyuan ;
Huang, Jianfeng ;
Fan, Zhongjie ;
Gu, Dongfeng .
HUMAN GENETICS, 2009, 125 (01) :11-20
[7]  
Johnson A, 2004, CIRCULATION, V110, P590
[8]   Lp-PLA2 Inhibition-The Atherosclerosis Panacea? [J].
Karakas, Mahir ;
Koenig, Wolfgang .
PHARMACEUTICALS, 2010, 3 (05) :1360-1373
[9]   Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis [J].
Kolodgie, Frank D. ;
Burke, Allen P. ;
Skorija, Kristi S. ;
Ladich, Elena ;
Kutys, Robert ;
Makuria, Addisalem Taye ;
Virmani, Renu .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (11) :2523-2529
[10]   Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction [J].
Liu, PY ;
Li, YH ;
Wu, HL ;
Chao, TH ;
Tsai, LM ;
Lin, LJ ;
Shi, GY ;
Chen, JH .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (05) :1023-1028